Depomed inks $50M licensing deal on Proquin

Esprit Pharma will pay $50 million for US sales and marketing rights to Proquin XR, Depomed's recently approved extended-release treatment for urinary tract infections. In addition to the $50 million licensing fee--including a $30 million upfront payment--Esprit will pay 15 percent to 25 percent royalties on net sales. Esprit also has right of refusal for marketing rights in Canada.

- read this release for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.